From a renal perspective, mTOR inhibitors promote growth control and hinder the progression of angiomyolipoma, reducing the need for surgical and invasive interventions such as nephrectomy and repeated embolizations, which lead to loss of renal mass and function4,17,19. The gene discussed is MTOR; the disease is angiomyolipoma.